After spinning off its diabetes business as MiniMed (MMED), Medtronic (MDT) received about 55 million of its own shares in the final results of its oversubscribed split-off and exchange offer, so future net income will be spread across fewer shares, which the article says can support EPS growth. It gives three points: Medtronic has raised its dividend for 49 consecutive years and could reach the 50-year mark if it raises the dividend in 2027 as expected, while only 59 of roughly 7,000 major U.S.-listed stocks are on the “Dividend King” list; and its trailing cash dividend payout ratio is just under 60%. Revenue in the first quarter of fiscal 2027 rose nearly 14% to $9.8 billion, and EPS rose 15% to $1.45. Fiscal 2026 revenue reached $36.4 billion, up 8.4%, supported by more than 50 new FDA approvals and clearances. The stock trades at about 16 times forward earnings and 24 times trailing earnings, below Johnson & Johnson, Edwards Lifesciences, Abbott Labs and Stryker.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
dividendshealthcareearningsvaluation
Open a keyword to see other news on the same topic.
Related news
- How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King?
Medtronic has raised its quarterly dividend for 49 consecutive years, one year short of Dividend King status, which requires 50 years. At an annualized dividend of $2.88 per share, roughly 348 shares, costing about $32,792, would generate $1,002.24 in annual dividend income, a yield of around 3%. Recent dividend increases have been modest, at 1.4% this year and an average of 2% over three years. The spinoff of MiniMed, its lower-margin diabetes business, completed via an exchange offer this week, lets Medtronic focus on its higher-margin cardiovascular, neuroscience and surgical businesses. Analysts estimate earnings growth of 8.1% and 7.1% for the fiscal years ending January 2027 and January 2028, and with a 48% forward payout ratio, that could support larger dividend increases.
- Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
Pfizer shares are up 18% this year, shaping up as their best year since 2021, when they rose more than 60%. The stock remains down around 30% over five years. The author says money may be rotating from tech into healthcare, citing two unnamed ETFs. Pfizer's 5.8% yield is one of the highest on the S&P 500, more than five times the index's 1% average. Its trailing P/E of 37 is inflated by restructuring and impairment charges, while its forward P/E is around 10, which the author argues shows the stock is still undervalued.
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson recorded about $7 billion in charges in Q3 2026, including a proposed talc litigation resolution and expenses tied to the Firefly Bio transaction and a Sail Biomedicines collaboration, which weighed heavily on earnings. Despite this, the company raised its full-year revenue and earnings guidance, with quarterly revenue up nearly 6% while GAAP earnings per share fell about 96%. The proposed talc settlement totals $5.5 billion, with an initial $3 billion payment due in 2027 and the remainder paid in later years. The author views the settlement as a net positive that could let J&J focus on long-term growth, noting that healthcare spending tends to hold up in recessions. J&J has increased its dividend for 64 consecutive years, which the author cites as evidence of the company's resilience.
- This Dividend King Just Announced Great News for Investors
Abbott Laboratories reported third-quarter sales of $13 billion, up 7% on a comparable basis, and adjusted EPS of $1.42, up 9% year over year. Medical devices ($5.8 billion, up 7.8%) and established pharmaceuticals ($1.6 billion, up 8.4%) were the main growth drivers, while nutrition grew slowest ($2.3 billion, up 4.9%), with the article citing headwinds including a 2022 infant formula recall and lawsuits over formula for premature infants. Abbott will spin off the nutrition segment into a stand-alone company, which the article says could support stronger long-term revenue, earnings and margins while helping the unit avoid its legal and regulatory obstacles. Abbott closed its $21 billion cash acquisition of Exact Sciences, and diabetes care ($2.2 billion, up 6.7%), led by the FreeStyle Libre CGM system, remains an important driver; Abbott estimates 70 million to 80 million of the half-billion people with diabetes worldwide could benefit from CGM, versus about 10 million to 12 million current users. The article also notes Abbott's Dividend King status, meaning at least 50 consecutive years of dividend increases.
- Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Johnson & Johnson's third-quarter revenue rose 6% to $25.9 billion and adjusted EPS of $2.59 fell 7.5% year over year, both topping most analyst estimates, and the company raised its full-year 2026 operational sales growth guidance to 6.4% to 6.8%. However, MedTech revenue rose only 2.5% to $8.6 billion, short of the consensus of just over $8.7 billion, and the stock fell nearly 6% after the release; CFO Joe Wolk called the division's results 'disappointing,' and the company floated a spinoff of its DePuy Synthes orthopedics business sometime in 2027. The article notes MedTech accounts for about one-third of sales and under 20% of adjusted net income, while oncology grew more than 16% to $7.6 billion in the quarter, with J&J targeting at least $50 billion in oncology sales by 2030. It also highlights a forward dividend yield of about 2% backed by a 64-year dividend growth streak as a reason the stock may be easier to hold through volatility.
- Is UnitedHealth Group Stock a Buy After Another Solid Quarter?
UnitedHealth beat expectations in Q3, with revenue of $112.7 billion (versus $113.2 billion a year earlier and $111.4 billion expected) and adjusted EPS of $4.69 against Wall Street's $4.14 estimate. The company raised its full-year adjusted EPS guidance to at least $20.50, from the previous $19.50 to $20, helped by exiting unprofitable markets and investing in AI. The stock closed just over $401 last week and is up around 22% in 2026, though its five-year returns remain negative. The article says the forward P/E of around 16 is below the more than 19 times that the average S&P 500 stock trades at, and the 2.3% dividend yield adds appeal for income investors. It concludes UnitedHealth remains a worthwhile option given its modest valuation and improving earnings.
Related markets
Latest news
- Cybercab Expansion Might Change The Case For Investing In Tesla Stock (TSLA)
Tesla is expanding its Cybercab robotaxi service after regulators in Texas and Nevada authorized larger fleets and pilot operations in key U.S. cities. The article says this low-cost, software-heavy model could help Tesla build recurring service revenue on its EV base, but heavy spending on autonomy, chips and energy, along with R&D and capex, keeps auto margins under pressure. Third-quarter revenue was roughly flat year on year, while net income and EPS fell. A Turo partnership lets renters use verified FSD Supervised cars, with a one-month trial for eligible U.S. hosts. Consensus analyst forecasts put Tesla at US$185.3 billion in revenue and US$17.8 billion in earnings by 2029, with 21.4% yearly revenue growth, while the lowest forecasts reach only US$136.0 billion and US$4.6 billion.
- Pentagon urges Baltic NATO members to stop 'provoking' Russia
According to four sources close to the matter, US Under Secretary of Defense Elbridge Colby has privately urged officials in Lithuania, Latvia and Estonia to refrain from 'provoking' Russia, and pressed Estonia to be cautious in its public statements. The Pentagon declined to comment on the private exchanges, and it is unclear whether other NATO allies received similar warnings. The message follows sharp rhetoric from Baltic leaders, including Estonia's prime minister comparing Vladimir Putin to a 'cornered rat' and Latvia's foreign minister accusing Russia of 'state-sponsored terrorism' over an explosive-laden drone found at a German airport, which Putin denied. The development comes as Washington temporarily eased sanctions to allow Russian diesel imports after a 9 October call between President Trump and Putin.
- AMZN Q3 deep dive: cloud surge and AI investments drive mixed market reception
Amazon's third-quarter 2026 revenue rose 12.1% year on year to $201.9 billion, in line with the $202.3 billion analyst estimate, while GAAP EPS of $1.89 missed the $1.96 expectation by 3.4%. Operating margin widened to 13.9% from 9.7% a year earlier. AWS grew 39.3%, its fastest pace in nearly five years and an acceleration for a sixth straight quarter, driven by AI infrastructure demand and custom chips such as Trainium and Graviton, which saved customers more than $2 billion in Q3 alone. Management expects next-quarter revenue of about $243.5 billion and said it believes AWS can grow north of 40% in 2027 and 2028, although near-term profitability may fluctuate with higher operating costs. Prime members ordering groceries with same-day delivery have tripled, and advertising growth is expected to return to the high teens after a slowdown tied to Prime Day timing.
- Many companies put profits 'in reverse' over the past nine months
Several companies reported sharp profit declines for the first nine months. Tin Nghia (TID) posted after-tax profit of over 234 billion VND, down 69%, and has completed 52% of its annual plan, while Thuduc House (TDH) recorded an after-tax loss of over 1 billion VND versus a profit of over 103 billion VND a year earlier, largely due to a high base from a court win against the Ho Chi Minh City tax authority. DICERA (DC4) saw nine-month revenue fall 27% and profit drop 9%, with operating cash flow negative by over 115 billion VND compared with a positive 459 billion VND a year earlier. DIC Corp (DIG) posted after-tax profit of over 202 billion VND, up more than 1%, but its revenue fell 14% and only 40% of its annual plan is complete. In the week, the VN-Index dropped 32.53 points to 1,741.62, and foreign investors were net sellers of nearly 84 million units worth over 2,531 billion VND across the market.
- VNG posts first profit exceeding 1,000 billion VND
VNG's third-quarter revenue reached over 3,360 billion VND, up 22% year on year, and after-tax profit of 420 billion VND extended its run to three consecutive profitable quarters. For the first nine months, revenue totaled over 9,230 billion VND and after-tax profit reached 1,012 billion VND, the first time the company has crossed the 1,000 billion VND mark since listing at the end of 2022. Online games remained the main driver at about 66% of revenue, while fintech service Zalopay's revenue nearly doubled to 750 billion VND. As of end-September, total assets were nearly 13,000 billion VND and liabilities nearly 11,700 billion VND, and the company expects AI products and services to account for at least 20% of revenue by 2030. VNZ shares closed the last session of October at 533,000 VND, giving a market capitalization of over 16,000 billion VND.
- Arctic Giant: What the West “Doesn’t Want to Reveal” About Russia’s Northern Border Region
An RT article argues that Russia, which holds about 53% of the Arctic coastline, sees major economic, commercial and military potential in the region amid competition with the West. As ice melts, Moscow aims to turn the Northern Sea Route into a profitable trade link between Europe and Asia, while the Arctic is warming nearly four times faster than the global average. EU foreign policy chief Kaja Kallas described the region on October 20 as the “frontline of global power competition” and accused Moscow of militarizing it, while Russia denies threatening anyone and says NATO is escalating tensions. Estimates of undiscovered but recoverable resources put the Arctic at about 90 billion barrels of oil and 1,669 trillion cubic feet of natural gas, and Russia was the first country to formally submit an extended continental shelf claim to the UN in 2001.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.